Cytokines and Genes in Therapeutic Response in Crohn's Disease
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Irritable Bowel Syndrome (IBS), Gastrointestinal, Crohns Disease |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/22/2018 |
| Start Date: | October 13, 2017 |
| End Date: | October 2020 |
Inflammatory bowel disease (IBD), consisting of two major forms, Crohn's disease (CD) and
ulcerative colitis (UC), affects more than 1.6 million people in the United States alone.
Though the precise mechanisms underlying the inflammation and immune responses in IBD are
still being investigated, various inflammatory mediators, including pro-inflammatory
cytokines, and genes have been implicated in the disease process. At present, there are no
reliable mechanisms to predict response to individual IBD medications. The investigators seek
to evaluate whether inflammatory cytokines change longitudinally during treatment with
anti-cytokine agents in both treatment primary responders and primary non-responders. In
addition, the investigators will be evaluating the pharmacogenetics of treatment response to
these agents.
ulcerative colitis (UC), affects more than 1.6 million people in the United States alone.
Though the precise mechanisms underlying the inflammation and immune responses in IBD are
still being investigated, various inflammatory mediators, including pro-inflammatory
cytokines, and genes have been implicated in the disease process. At present, there are no
reliable mechanisms to predict response to individual IBD medications. The investigators seek
to evaluate whether inflammatory cytokines change longitudinally during treatment with
anti-cytokine agents in both treatment primary responders and primary non-responders. In
addition, the investigators will be evaluating the pharmacogenetics of treatment response to
these agents.
Inclusion Criteria:
- Patients that are seen in the Inflammatory Bowel Disease clinic with Crohn's disease
who are initiating either treatment as part of their routine clinical care.
- Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or
other non-IBD related indication.
Exclusion Criteria:
- pregnant
- have a known coagulopathy or bleeding disorder
- have known renal or hepatic impairment
- have a history of organ transplantation
- CD patients who are being seen in consultation and do not plan to receive longitudinal
care through initiation their new therapy at the Vanderbilt IBD center will be
excluded.
We found this trial at
2
sites
Click here to add this to my saved trials
1211 21st Avenue South
Nashville, Tennessee 37212
Nashville, Tennessee 37212
Click here to add this to my saved trials